Truberzi (eluxadoline)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- eluxadoline
- Company
- Allergan Pharmaceuticals International Limited
- Status
- Withdrawn
- Therapeutic area
- Irritable Bowel Syndrome; Diarrhea
- CHMP opinion
- Thu 21 Jul 2016
- EU approval
- Mon 19 Sep 2016
- Designations
- Additional monitoring
- Application
- EMEA/H/C/004098
- ATC
- A07
- Official record
- www.ema.europa.eu
Indication
Truberzi is indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS D).
Regulatory milestones
No milestones recorded in the last year.
Follow Truberzi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.